Large Swedish Study Suggests Low Overall Risk of Sudden Vision Loss with GLP-1 RA Use
A nationwide cohort study found a slightly higher risk for nonarteritic anterior ischemic optic neuropathy (NAION) among users of glucagon-like peptide-1 receptor agonists (GLP-1RAs) compared with…
Read the full articleYou might also wanna read
GLP-1 Receptor Agonists and Eye Safety: Examining the NAION Risk at ADA 2025
Do their associations with nonarteritic anterior ischemic optic neuropathy and other adverse outcomes make these drugs more risky than benef
mdsc.pe·22h agoStudy Probes Absolute Risk for ION With GLP-1 Agents
In patients with type 2 diabetes, GLP-1 RAs may be associated with a higher incidence of ischemic optic neuropathy than other medications, c
GLP-1s and Blinding Condition; Cyclosporiasis Source Found? Tylenol-Autism Lawsuits
(MedPage Today) -- Note that some links may require registration or subscription. A cohort study found that diabetes patients taking GLP-1 r
Updates in Non-Arteritic Ischemic Optic Neuropathy - Part 2
In the second episode of this two-part series, Drs. Justin Abbatemarco, Valérie Biousse, and Nancy J. Newman discuss the risk of non-arterit
GLP-1 Receptor Agonists Linked to Small Risk of Smell and Taste Disturbances in Type 2 Diabetes
The absolute risk appears low, but new data suggest small changes in smell and taste with GLP-1 treatment may exceed those already associate
mdsc.pe·15d ago
Oral small-molecule GLP-1 RA improves blood glucose and weight reduction
The VISTA and SOLSTICE phase 2b trials evaluated the use of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) elecoglipron in adults.
Comments
Sign in to join the conversation.
No comments yet. Be the first.